Cosmo Robotics, a pioneer in wearable robotics, is gearing up for its highly anticipated public subscription for general investors, scheduled for April 27 and 28, 2026. The company, which specializes in developing rehabilitation robots for patients with stroke, cerebral palsy, and spinal cord injuries, as well as industrial wearable robots designed to reduce physical strain on workers, is making headlines as it prepares to list on South Korea’s KOSDAQ market next month.
According to multiple reports, including those from Dailyan and TF Media, Cosmo Robotics concluded its institutional investor demand forecasting between April 16 and April 22, 2026. Out of the total 4.17 million shares available for public offering, 2,906,300 shares—representing 69.7%—were allocated for this preliminary process. The results were nothing short of remarkable: 2,257 institutional investors participated, generating a staggering competition rate of 1,140.11 to 1. This overwhelming demand led the company to set its public offering price at the top of its hoped-for price band, 6,000 KRW per share, with the total public offering size reaching approximately 25 billion KRW.
Cosmo Robotics is no stranger to innovation. The company, formerly known as ExoAthlete Asia, has carved out a niche by manufacturing and selling advanced exoskeleton robots for adults and children, along with strength-assist robots and home-use medical devices that have received—or are pursuing—FDA Home Use certification. The firm prides itself on developing all core technologies in-house, spanning mechanical, electrical, electronic, and software domains, ensuring full control over the quality and performance of its lower limb exoskeleton robots.
The public subscription for general investors will take place over two days, April 27 and 28, 2026. In tandem, on April 27, Cosmo Robotics will also offer 221,200 shares (5.3% of the total) to its employee stock ownership association, further aligning the interests of its workforce with the company’s future growth. The underwriters orchestrating this IPO are Eugene Investment & Securities and NH Investment & Securities, both well-known players in the South Korean financial sector.
Once the IPO process is complete, Cosmo Robotics is set to make its debut on the KOSDAQ market on May 11, 2026, provided all goes according to plan. The funds raised from this public offering are earmarked for several strategic initiatives. As outlined in statements from company officials and reported by Dailyan, the capital will be used for expanding factory facilities, introducing new processing equipment, ramping up research and development, and bolstering both domestic and overseas marketing efforts.
One of the company’s top priorities is to move away from outsourcing its manufacturing processes. "We aim to secure core component technology and reduce costs by shifting to direct processing," a Cosmo Robotics spokesperson explained, as quoted by Dailyan. This shift is expected to enhance the company’s ability to innovate while keeping expenses in check—an essential step as it targets the development of affordable, home-based rehabilitation products. "We want to focus on developing 'Home Use' products that allow individuals to undergo rehabilitation training at home or on their own at minimal cost," the spokesperson added.
The company’s ambitions extend beyond the domestic market. Cosmo Robotics is actively working on product development for pediatric (BAM-T, BAM-K) and personal (EA Personal) wearable robots, with an eye toward securing U.S. FDA certification for these devices. Such certification would open doors to the lucrative and highly regulated American healthcare market. In addition, a portion of the IPO proceeds will be invested in advancing ExoCloud, the company’s proprietary cloud platform designed to support its wearable robotics ecosystem.
However, investors are being cautioned about a notable aspect of the IPO. According to reports from Dailyan and TF Media, 32.06% of Cosmo Robotics’ shares will be freely tradable immediately upon listing. This substantial float means that a significant volume of shares could hit the market as soon as trading begins, potentially impacting the stock price—either through increased volatility or downward pressure if early holders decide to cash in their gains.
Financially, Cosmo Robotics reported consolidated operating revenue of approximately 11.5 billion KRW in 2025, alongside an operating loss of about 8 billion KRW, as noted in industry summaries. While the company is not yet profitable, its robust revenue and aggressive investment in research and development signal a commitment to long-term growth. The leadership is betting that the infusion of capital from the IPO will accelerate its journey toward profitability and market leadership.
Cosmo Robotics’ IPO is not happening in isolation. The company is part of a wave of technology-driven firms tapping the public markets in late April and early May 2026. For example, MakinaRocks, a developer of industrial AI solutions, is conducting its own demand forecasting from April 28 to May 6, with a price band of 12,500 to 15,000 KRW. Meanwhile, Chaebi is slated to list on April 29, with a public offering amount of 110.7 billion KRW, and Shinhan 18th SPAC will debut on April 30, targeting investments in high-growth industries such as biotech, software, and renewable energy.
Yet, Cosmo Robotics stands out for its focus on wearable robotics—a field with enormous potential as populations age and demand for rehabilitation and assistive technologies grows worldwide. The company’s strategy of developing core technologies in-house, pursuing rigorous regulatory approvals, and investing in next-generation cloud services positions it at the forefront of this emerging industry.
As the subscription period opens, all eyes are on Cosmo Robotics to see whether its bold vision and innovative products will translate into market success. The outcome will not only shape the company’s future but could also influence the trajectory of South Korea’s robotics and medical device sectors for years to come.
With the IPO set to close and the KOSDAQ listing on the horizon, Cosmo Robotics is entering a critical chapter in its journey—one that will test its ability to deliver on high expectations and drive meaningful change in the lives of patients and workers alike.